A new study released today in the Journal of the American Medical Association found that Medicare beneficiaries experienced no major changes in access to quality cancer care following passage of the Medicare Prescription Drug Improvement and Modernization Act (MMA) of 2003. 

The study, funded by the Global Access Project (a collaboration organized by the National Patient Advocate Foundation in 2004) and led by investigators from the Duke Clinical Research Institute, found that some patients are now experiencing increased waiting periods for their chemotherapy treatments; however, in conclusion the study suggests no significant adverse effects resulting from this legislation.  Further research may be beneficial in order to ensure patients are receiving the safest and highest-quality care possible. 

 Read Press Release.